#psmaddition search results

Expert #ProstateCancer panel #UromigosLive day 2 in #PSMAddition met rPFS ❓will OS be positive (immature, allowed crossover) ❓QoL vs AE ❓long-term tox - renal & 2ary malignancies ❓do all pts need all 6 doses ❓better pt selection - SUVmean or total PSMA tumor volume

Interim #PSMAddition analysis shows lutetium PSMA-617 improves rPFS in #mHSPC. @DrScottTagawa @WeillCornell joins Oliver Sartor, MD @EJHospital to discuss on UroToday > bit.ly/4hLFCiJ @PCFnews @PCF_Science #PCFRetreat25

#PSMAddition: PhIII, LuPSMA + ADT + ARPi vs. ADT + ARPi in mHSPC 🎯rPFS ⬆️w/LuPSMA (primary endpoint met) (HR 0.72) ⚠️OS immature 🚀 LuPSMA triplet likely joining mHSPC intensification options soon #MedTwitter #OncTwitter #OncTwitter #MedX

At #ESMO25, Scott Tagawa, MD, discusses results from the #PSMAddition trial evaluating the addition of 177Lu-PSMA-617 to ADT and ARPI therapy for patients with metastatic hormone-sensitive prostate cancer. Learn more: hmpgloballearningnetwork.com/site/onc/video… #medtwitter #onctwitter

5 GU studies that we focused on during our conference highlight discussion with @bergsa83 from #ESMO25: ✅ #PSMAddition by @DrScottTagawa ✅ #CAPItello281 ✅ #POTOMAC ✅ #Keynote905/EV303 ✅ #IMvigor011 by @tompowles1 #gusm #OncTwitter #MedTwitter @OncUpdates

GU Malignancy Highlights from #ESMO25 w/ @bergsa83! 5 key studies: ✅ #PSMAddition ✅ #CAPItello281 ✅ #POTOMAC ✅ #Keynote905 ✅ #IMvigor011 Full Discussion: - oncbrothers.com/esmo-gu-2025 - Also on the “Oncology Brothers” podcast #OncTwitter #gusm @OncUpdates @myESMO

#Prostatakrebs: Radioligandentherapie erfolgreich bei hormonsensitiven #Tumoren geprüft. #PSMAddition-Studie vom @myESMO-Kongress deutet darauf hin, dass nicht nur Patienten mit metastasiertem kastrationsresistenten #Prostatakarzinom profitieren. tinyurl.com/2ypw4kt8

A reflection of key prostate studies at @myESMO #ESMO25, starting with #PSMAddition. First positive study of a radioligand in mHSPC, with significant PFS improvement (HR 0.72), favourable safety profile. Complete response rates notably higher, 57% and 42% 1/4

Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive #mHSPC #PSMAddition. Presentation by @AzadOncology @PeterMacCC. #ESMO25 written coverage by @RKSayyid @UAUrology > bit.ly/3WRb2u8 @myESMO

#ESMO25 Abstract Highlights! #PSMAddition: PhIII, LuPSMA + ADT + ARPi vs. ADT + ARPi in mHSPC 🎯rPFS ⬆️w/LuPSMA (primary endpoint met) (HR 0.72) ⚠️OS immature 🚀 LuPSMA triplet likely joining mHSPC intensification options soon #MedTwitter #OncTwitter #OncTwitter #MedX

@AzadOncology delivered one of the most thorough and balanced discussions I’ve ever heard. Excellent summary ⬇️. Congratulations to @DrScottTagawa on an excellent presentation and to the #PSMAddition investigators for addressing the role of Lu-PSMA-617 in mHSPC. #ESMO25…

1. #PSMAddition: PhIII, LuPSMA + ADT + ARPi vs. ADT + ARPi in mHSPC - rPFS ⬆️ with LuPSMA (HR: 0.72) - Higher xerostomia & neutropenia - How many of these pts would’ve received Chemo + ADT +ARPi today outside trial? - This will likely be another triplet available soon 3/11

Day 3 #ESMO25 Highlights: Prostate Ca 1. #PSMAddition: LuPSMA in mHSPC 2. #ENZARD: ADT+XRT+/-Enza 3. #EMBARK: Enza biochem recurrent Prostate Ca 4. #CAPItello281: Abi+/-Capi in PTEN Mesothelioma: 5. #DREAM3R: Durva+Chemo 1L #OncTwitter @OncUpdates @OncoAlert 1/11

Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive #ProstateCancer #PSMAddition. Presented by @DrScottTagawa @WeillCornell. #ESMO25 written coverage by @RKSayyid @UAUrology > bit.ly/4nZfS4N @myESMO

🎯Patient individualisation is a Must! For Patient selection and follow up! The aim is that the Patient live longer BUT also BETTER 🥇 #qualityoflife #PSMAddition #ESMO25 #prostatacancer @DrScottTagawa

Breakthrough in #PSMAddition: 177Lu-PSMA-617+ ADT+ARPi significant improve rPFS in patients with PSMA-pos mHSPC. Data reveals an HR of 0.27. Adverse event profile remained within expected for #Lu177PSMA treatment with no unexpected increases when combined with ADT+ARPI #ESMO25

#PSMAddition (LBA6, #ESMO25 )The phase 3 PSMAddition trial brings radioligand therapy into the mHSPC setting. In 1,144 PSMA+ patients, adding [^177Lu]Lu-PSMA-617 to ADT + ARPI significantly improved rPFS (HR 0.72, p = 0.002) ✅ 85% completed all 6 Lu-PSMA cycles.

As presented at #ESMO25, second interim analysis results from the #PSMAddition trial showed that adding 177Lu-PSMA-617 to standard ADT plus an ARPI significantly improved rPFS in metastatic hormone-sensitive prostate cancer. Learn more: hmpgloballearningnetwork.com/site/onc/news/…

#PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 + standard of care and standard of care alone in patients with #mHSPC. Presentation by @DrScottTagawa @WeillCornell. #ASCO23 written coverage by @zklaassen_md @GACancerCenter > bit.ly/3CdnCda @ASCO

Want to learn about trials in progress at #ASCO23? Check out abstract no. TPS5116 on Sat, June 3 from 8 to 11 AM CDT for the latest Novartis presentation from the #PSMAddition Phase 3 study on RLT plus SOC vs SOC alone in patients with metastatic hormone-sensitive prostate cancer

🎯Patient individualisation is a Must! For Patient selection and follow up! The aim is that the Patient live longer BUT also BETTER 🥇 #qualityoflife #PSMAddition #ESMO25 #prostatacancer @DrScottTagawa

A reflection of key prostate studies at @myESMO #ESMO25, starting with #PSMAddition. First positive study of a radioligand in mHSPC, with significant PFS improvement (HR 0.72), favourable safety profile. Complete response rates notably higher, 57% and 42% 1/4

#PSMAddition (LBA6, #ESMO25 )The phase 3 PSMAddition trial brings radioligand therapy into the mHSPC setting. In 1,144 PSMA+ patients, adding [^177Lu]Lu-PSMA-617 to ADT + ARPI significantly improved rPFS (HR 0.72, p = 0.002) ✅ 85% completed all 6 Lu-PSMA cycles.

Breakthrough in #PSMAddition: 177Lu-PSMA-617+ ADT+ARPi significant improve rPFS in patients with PSMA-pos mHSPC. Data reveals an HR of 0.27. Adverse event profile remained within expected for #Lu177PSMA treatment with no unexpected increases when combined with ADT+ARPI #ESMO25

5 GU studies that we focused on during our conference highlight discussion with @bergsa83 from #ESMO25: ✅ #PSMAddition by @DrScottTagawa ✅ #CAPItello281 ✅ #POTOMAC ✅ #Keynote905/EV303 ✅ #IMvigor011 by @tompowles1 #gusm #OncTwitter #MedTwitter @OncUpdates

1. #PSMAddition: PhIII, LuPSMA + ADT + ARPi vs. ADT + ARPi in mHSPC - rPFS ⬆️ with LuPSMA (HR: 0.72) - Higher xerostomia & neutropenia - How many of these pts would’ve received Chemo + ADT +ARPi today outside trial? - This will likely be another triplet available soon 3/11

#ESMO25 Abstract Highlights! #PSMAddition: PhIII, LuPSMA + ADT + ARPi vs. ADT + ARPi in mHSPC 🎯rPFS ⬆️w/LuPSMA (primary endpoint met) (HR 0.72) ⚠️OS immature 🚀 LuPSMA triplet likely joining mHSPC intensification options soon #MedTwitter #OncTwitter #OncTwitter #MedX

Day 3 #ESMO25 Highlights: Prostate Ca 1. #PSMAddition: LuPSMA in mHSPC 2. #ENZARD: ADT+XRT+/-Enza 3. #EMBARK: Enza biochem recurrent Prostate Ca 4. #CAPItello281: Abi+/-Capi in PTEN Mesothelioma: 5. #DREAM3R: Durva+Chemo 1L #OncTwitter @OncUpdates @OncoAlert 1/11

As presented at #ESMO25, second interim analysis results from the #PSMAddition trial showed that adding 177Lu-PSMA-617 to standard ADT plus an ARPI significantly improved rPFS in metastatic hormone-sensitive prostate cancer. Learn more: hmpgloballearningnetwork.com/site/onc/news/…

@AzadOncology delivered one of the most thorough and balanced discussions I’ve ever heard. Excellent summary ⬇️. Congratulations to @DrScottTagawa on an excellent presentation and to the #PSMAddition investigators for addressing the role of Lu-PSMA-617 in mHSPC. #ESMO25…

At #ESMO25, Scott Tagawa, MD, discusses results from the #PSMAddition trial evaluating the addition of 177Lu-PSMA-617 to ADT and ARPI therapy for patients with metastatic hormone-sensitive prostate cancer. Learn more: hmpgloballearningnetwork.com/site/onc/video… #medtwitter #onctwitter

#PSMAddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 + Standard of Care vs SOC alone in patients with #mHSPC. Presentation by @DrScottTagawa @WeillCornell. #ESMO21 written coverage by @WallisCJD @UofT on UroToday > bit.ly/3Epp0cn @myESMO

#PSMAddition: PhIII, LuPSMA + ADT + ARPi vs. ADT + ARPi in mHSPC 🎯rPFS ⬆️w/LuPSMA (primary endpoint met) (HR 0.72) ⚠️OS immature 🚀 LuPSMA triplet likely joining mHSPC intensification options soon #MedTwitter #OncTwitter #OncTwitter #MedX

Interim #PSMAddition analysis shows lutetium PSMA-617 improves rPFS in #mHSPC. @DrScottTagawa @WeillCornell joins Oliver Sartor, MD @EJHospital to discuss on UroToday > bit.ly/4hLFCiJ @PCFnews @PCF_Science #PCFRetreat25

Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive #ProstateCancer #PSMAddition. Presented by @DrScottTagawa @WeillCornell. #ESMO25 written coverage by @RKSayyid @UAUrology > bit.ly/4nZfS4N @myESMO

Expert #ProstateCancer panel #UromigosLive day 2 in #PSMAddition met rPFS ❓will OS be positive (immature, allowed crossover) ❓QoL vs AE ❓long-term tox - renal & 2ary malignancies ❓do all pts need all 6 doses ❓better pt selection - SUVmean or total PSMA tumor volume

#PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 + standard of care and standard of care alone in patients with #mHSPC. Presentation by @DrScottTagawa @WeillCornell. #ASCO23 written coverage by @zklaassen_md @GACancerCenter > bit.ly/3CdnCda @ASCO